Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses

American Journal of Veterinary Research

Volumn 71, Issue 3, 2010, Pages 337-341

  Moore, Sarah A ^a,b   Muñana, Karen R ^a   Papich, Mark G ^a   Nettifee Osborne, Julie ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; COMPARTMENT MODEL; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; ANTICONVULSANTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; HALF-LIFE; KINETICS; METABOLIC CLEARANCE RATE; PIRACETAM;

ANIMALIA; CANIS FAMILIARIS;

EID: 77950965044     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.71.3.337     Document Type: Article

References (13)

1. Schwartz-Porsche D. Epidemiological, clinical and pharmacokinetic studies in spontaneously epileptic dogs and cats, in Proceedings. 4th Annu Vet Med Forum Am Coll Vet Intern Med 1986;11-61-11-63.
2. Podell M, Fenner WR, Powers JD. Seizure classification in dogs from a nonreferral-based population. J Am Vet Med Assoc 1995;206:1721-1728.
3. Schwartz-Porsche D, Loscher W, Frey HH. Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison. J Vet Pharmacol Ther 1985;8:113-119.
4. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006;45:1061-1075.
5. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242. (Pubitemid 30604624)
6. Nicolas JM, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 1999;27:250-254.
7. Gidal BE, Baltès E, Otoul C, et al. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res 2005;64:1-11. (Pubitemid 40726160)
8. Dewey CW, Bailey KS, Boothe DM, et al. Pharmacokinetics of single-dose intravenous levetiracetam administration in normal dogs. J Vet Emerg Crit Care 2008;18:153-157. (Pubitemid 351463977)
9. Volk HA, Matiasek LA, Luján Feliu-Pascual A, et al. The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. Vet J 2008;176:310-319.
10. Isoherranen N, Yagen B, Soback S, et al. Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. Epilepsia 2001;42:825-830. (Pubitemid 32783088)
11. Patterson EE, Goel V, Cloyd JC, et al. Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics. J Vet Pharmacol Ther 2008;31:253-258. (Pubitemid 351677391)
12. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criteria (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175. (Pubitemid 8384279)
13. Kampa N, Boström I, Lord P, et al. Day-to-day variability in glomerular filtration rate in normal dogs by scintigraphic technique. J Vet Med A Physiol Pathol Clin Med 2003;50:37-41.